Efficacy of combined VEGFR1–3, PDGFα/β, and FGFR1–3 blockade using nintedanib for esophagogastric cancer

PURPOSE: Vascular endothelial growth factor receptor 2 (VEGFR2)-directed therapy is commonly used to treat metastatic esophagogastric cancer, but disease progresses in most patients within months. Therapeutic resistance is likely mediated in part by co-occurring amplifications of the genes for multi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: Won, Elizabeth, Basunia, Azfar, Chatila, Walid K., Hechtman, Jaclyn F., Chou, Joanne F., Ku, Geoffrey Y., Chalasani, Sree B., Boyar, Michelle S., Goldberg, Zoe, Desai, Avni M., Tuvy, Yaelle, Berger, Michael F., Tang, Laura, Kelsen, David P., Schattner, Mark, Ilson, David H., Capanu, Marinela, Solit, David B., Schultz, Nikolaus, Janjigian, Yelena Y.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606369/
https://ncbi.nlm.nih.gov/pubmed/30952642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3789
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares